Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia

The present study compared the efficacy of cyclophosphamide combined with low-dose prednisolone in the treatment of idiopathic pulmonary fibrosis (IPF) with efficacy in idiopathic fibrosing nonspecific interstitial pneumonia fibrosing (NSIP). A total of 27 patients with IPF and 12 patients with fibrosing NSIP were included in this study. All patients had undergone surgical lung biopsy. The diagnoses were made based on clinical, radiological and pathological findings. All patients were treated with intermittent pulse therapy with methylprednisolone for 4 weeks, followed by cyclophosphamide with low-dose prednisolone. According to pulmonary function tests, four of 27 patients with IPF had improved, 22 remained unchanged, and one had worsened at the completion of pulse therapy. After 1 yr of combination therapy, four of 27 patients had improved, 14 remained unchanged, and nine had worsened. After pulse therapy, four of 12 patients with fibrosing NSIP had improved, and eight remained unchanged. After 1 yr of combination therapy, eight of 12 patients had improved, four remained unchanged, and none had worsened. Median survival of IPF patients was 4.1 yrs, which is significantly worse than that of fibrosing NSIP patients. In conclusion, patients with fibrosing nonspecific interstitial pneumonia had a more favourable response to combination therapy and a better survival than those with idiopathic pulmonary fibrosis.

[1]  R. Trisolini,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: report of a series , 2003, European Respiratory Journal.

[2]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[3]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[4]  A. Nicholson,et al.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. , 2000, American journal of respiratory and critical care medicine.

[5]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[6]  W. Travis,et al.  Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. , 2000, The American journal of surgical pathology.

[7]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[8]  A. Nicholson,et al.  A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. , 1999, American journal of respiratory and critical care medicine.

[9]  T. Colby,et al.  Erratum: Idiopathic nonspecific interstitial pneumonia/fibrosis: Comparison with idiopathic pulmonary fibrosis and BOOP (European Respiratory Journal (1998) 12 (1010-1019)) , 1999 .

[10]  T. Colby,et al.  Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. , 1998, The European respiratory journal.

[11]  T. Hartman,et al.  Idiopathic pulmonary fibrosis: current concepts. , 1998, Mayo Clinic proceedings.

[12]  V. Cottin,et al.  Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. , 1998, American journal of respiratory and critical care medicine.

[13]  J. Myers,et al.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. , 1998, American journal of respiratory and critical care medicine.

[14]  K P Offord,et al.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.

[15]  I. D. Johnston,et al.  British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. , 1997, Thorax.

[16]  J. Samet,et al.  Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. , 1996, Chest.

[17]  W. Black,et al.  The epidemiology of interstitial lung diseases. , 1994, American journal of respiratory and critical care medicine.

[18]  A. Katzenstein,et al.  Nonspecific Interstitial Pneumonia/Fibrosis: Histologic Features and Clinical Significance , 1994, The American journal of surgical pathology.

[19]  F. Barbé,et al.  [Bronchiolitis obliterans with organizing pneumonia]. , 1993, Anales de medicina interna.

[20]  Y. Kawabata,et al.  Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. , 1993, Chest.

[21]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.

[22]  J. Darbyshire,et al.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. , 1989, Thorax.

[23]  M. Schwarz,et al.  Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. , 1987, The American review of respiratory disease.

[24]  M. Turner-Warwick,et al.  The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. , 1987, The American review of respiratory disease.

[25]  J. Myers,et al.  Acute Interstitial Pneumonia: A Clinicopathologic, Ultrastmctural, and Cell Kinetic Study , 1986, The American journal of surgical pathology.

[26]  B. Burrows,et al.  Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival , 1980, Thorax.

[27]  R G Gupta,et al.  Natural history and treated course of usual and desquamative interstitial pneumonia. , 1978, The New England journal of medicine.

[28]  W. Roberts,et al.  Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. , 1976, Annals of internal medicine.